Elemental impurity risk management can help biomanufacturers to maintain regulatory alignment and ensure patient safety.
The attributes of the DS or DP that are to be tested to obtain the necessary information about product quality safety and efficacy are determined during the Drug Development stage. The information ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback